SuperGen Planning Dacogen NDA Submission For Myelodysplastic Syndrome In Third Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
The company plans to begin the fast-track decitabine NDA submission in the second quarter and complete submission in the third quarter. Pharmion’s MDS agent could come to market before then – Vidaza (azacitadine) has a user fee date of June 29.